Browsing by Author Pignata, Sandro

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2011Clinical Trials in Recurrent Ovarian CancerBeale, Philip; Alberts, David; Avall-Lundqvist, Elisabeth; Brady, Mark; et al, various; Friedlander, Michael; Harter, Philipp; Pignata, Sandro; Pujade- Lauraine, Eric; Sehouli, Jalid; Tinker, Anna; Trimble, Edward; Vergote, Ignace; Central Clinical School: MedicineClinical Trials in Recurrent Ovarian Cancer, International Journal Of Gynecological Cancer, vol.21, 4, 2011,pp 771-775
2011Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer.Brown, Christopher; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Delva, Remy; Donadello, Nicoletta; Friedlander, Michael L.; Georgoulopoulos, Alexander; Mirza, Mansoor Raza; Pignata, Sandro; Pujade-Lauraine, Eric; Schmalfeldt, Barbara; Southier, Philippe; Vergote, Ignace; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreEarly Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer., Journal of the National Cancer Institute, vol.103, 17, 2011,pp 1338-1342
2017Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialGebski, Val; et al, Various; Huzarski, Tomasz; Korach, Jacob; Ledermann, Jonathan; Oza, Amit M; Penson, Richard; Pignata, Sandro; Poveda, Andres; Pujade-Lauraine, Eric; Selle, Frederic; NH&MRC Clinical Trials CentreOlaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, The Lancet Oncology, vol.18, 9, 2017,pp 1274-1284
2010Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late RelapseBrown, Christopher; Gebski, Val; Aavall-Lundqvist, Elisabeth; du Bois, Andreas; Ferrero, Annamaria; Heywood, Mark; Jackisch, Christian; Joly, Florence; Kristensen, Gunnar; Le Fur, Nathalie; Lortholary, Alain; Pignata, Sandro; Pujade-Lauraine, Eric; Sehouli, Jalid; Vasey, Paul A.; Vergote, Ignace; Volgger, Birgit; Wagner, Uwe; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse, Journal of Clinical Oncology, vol.28, 20,pp 3323-3329
2017Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyBuizen, L; King, Madeleine; O'Connell, Rachel; Roncolato, Felicia; Stockler, Martin; Aotani, Enriko; Avall-Lundqvist, Elisabeth; Berek, Jonathan; Berton-Rigaud, Dominique; Donnellan, Paul; Feeney, Amanda; Friedlander, M; Heitz, Florian; Hilpert, Felix; Joly, F; Lanceley, Anne; Okamoto, Aikou; Oza, Amit; Pignata, Sandro; NH&MRC Clinical Trials Centre; Psychology; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreReducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study, The Oncologist, vol.22, 9, 2017,pp 1117-1124